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Abstract Junctional adhesion molecules (JAMs) are a family
of adhesion molecules localized at the tight junction of polar-
ized cells and on the cell surface of leukocytes. The last
20 years of research in this field has shown that several
members of the family play an important role in the regulation
of cell polarity, endothelium permeability and leukocytes mi-
gration. They mediate these pleiotropic functions through a
multitude of homophilic and heterophilic interactions with
intrafamily and extrafamily partners. In this article, we review
the current status of the JAM family and highlight their
functional role in tight junction dynamics and leukocyte
transmigration.
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Introduction
Epithelial and endothelial cells can assemble into cellular
sheets that form a physical barrier between different tissues.
To form these barriers, the cells establish and maintain several
different types of intercellular junctions. Tight junctions (TJs)
are the most apical type of junction, with the physical contact
point bordering as a belt on the upper lateral membrane of
polarized epithelial cells whereas adherens junctions, desmo-
somes and gap junctions are organized in a scattered lateral
distribution. At the level of the TJ, the intercellular space is
practically absent as the two cell membranes are in direct
contact with each other and can appear fused.
Many studies have been conducted over the last 50 years
that have specifically focused on the biology of cell junctions.
TJs were initially visualized as a fusion point or “kissing”
points between two adjacent cell membranes, thus explaining
why TJs were referred to as zonula occludens (Farquhar and
Palade 1963). The underlying functionality of these structures
was proposed in a later study using electron microscopy
where the diffusion of a tracer was observed to be restricted
across endothelial barriers in the mouse brain (Reese and
Karnovsky 1967). A few years later, it was confirmed that
occluding TJs of parenchymal brain capillaries and the epi-
thelial layer of choroid plexus form the structural basis of the
blood–brain barrier (BBB) (Brightman and Reese 1969). The
role of TJs in barrier formation was shown in studies that
measured transepithelial electrical resistance (TER), which
correlated directly with the number of TJ strands (Claude
1978; Claude and Goodenough 1973). In the 1980s, the new
freeze-fracture technology demonstrated that the enhanced
barrier functionality of the BBB may be mediated by the
extended numbers of tight junctional belts in the endothelium
of cerebral capillaries (Nagy et al. 1984). In these more recent
studies, it has become clear that the number of TJ strands and
the complexity of their ramification can vary significantly
between cell types and plays a key role in dictating barrier
function.
TJs form a molecular obstruction for solutes between the
apical and the basolateral domains of epithelial and endothe-
lial cells. Therefore, TJs are essential for the establishment and
the maintenance of cell polarity and act in coordination with
adherens junctions. However, TJs are not impermeable struc-
tures, they show a certain selectivity and specificity for ions
and molecules through aqueous pores and transporters
(Tsukita et al. 2001). For example, endothelial cells play a
key role in regulating the inflammatory response by
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controlling permeability and leukocyte trafficking processes
(Bazzoni and Dejana 2004).
Key to this function is the existence of an extensive array of
intracellular signaling molecules. Cell signaling events medi-
ated by cytoplasmic partners of TJ molecules have been
shown to modulate endothelial function by regulating prolif-
eration and differentiation processes (Guillemot et al. 2008;
Tsukita et al. 2001). TJs are composed of the transmembrane
proteins called occludin, the claudins and the junctional adhe-
sion molecules (JAMs) and the cytoplasmic polarity com-
plex molecules including ZO-1, AF-6, MUPP-1, MAGI-1,
cingulin and PAR-3 (Guillemot et al. 2008; Tsukita et al.
2001). The first proteins to be characterized were occludin
and the first two claudins (Furuse et al. 1998), which are part of
a family consisting in 24 members (Angelow et al. 2008). In
the cytoplasm, the ZO proteins, MUPP-1, cingulin, MAGI-1
and AF-6, form a dense plaque, which links the membrane
proteins to the actin cytoskeleton and transmits intracellular
signaling. Surprisingly, in occludin-deficient epithelia, the TJs
are still present and functional, which questioned the precise
role for occludin in the TJ structure. An essential role for this
molecule was confirmed in occludin-deficient animals where
impairment of epithelial barrier function was shown to lead to
growth retardation, male sterility and gastritis (Saitou et al.
2000). Meanwhile, claudins were shown to be essential mol-
ecules for forming a functional barrier (Angelow et al. 2008).
Indeed, exogenous expression of claudins in non-polarized
cells induced the neoformation of TJs and mediated tight cell-
to-cell adhesion (Angelow et al. 2008; Furuse and Tsukita
2006; Van Itallie and Anderson 2006). The different claudins
have a tissue specific distribution and the specificity of the TJ
barrier can be attributed to the type of Claudins found at the
junctions (Furuse and Tsukita 2006).
The JAMs are a family of transmembrane receptors local-
ized adjacent to TJs and can form homophilic and heterophilic
interactions at the adhesion contact. In contrast to Claudins,
transfection of JAMs into fibroblasts did not induce TJ strand
formation (Itoh et al. 2001). However, in endothelial cells, they
interact with polarity complex proteins through their PDZ
binding domains and are thought to regulate cell polarity and
leukocytes migration (Liang et al. 2000; Liu et al. 2000). In this
review, wewill discuss the current knowledge about the roles of
JAM proteins in the regulation of TJ dynamics.
The JAM family: structure and interaction
The JAM family belongs to the immunoglobulin super family
(Williams and Barclay 1988) and is composed of seven mem-
bers; three classical JAMs (JAM-A, B, C) and four related
proteins (JAM-4, JAM-L, CAR, ESAM) (Fig. 1). JAMs are
type I transmembrane glycoproteins, composed of two
immunoglobulin-like domains, one transmembrane domain
and one cytoplasmic tail of variable length containing a PDZ
domain (post-synaptic density protein (PSD95)), Drosophila
disc large tumor suppressor (Dlg1) and zonula occludens pro-
tein (ZO-1) binding motif. The Ig-like domains are of V type
and C2 type for JAM-B and JAM–C (Aurrand-Lions et al.
2001b). The V domain contains a J-like sequence and the C2-
type domain contains an extra disulfide bridge between cyste-
ines. Concerning JAM-A, the nature of the Ig domain was
initially described to contain 2 V-type domains, then proposed
to have two C2 domains and finally to have as JAM-B and -C,
one V-type and one C2-type domain (Aurrand-Lions et al.
2001b). Interestingly, the JAMs have significant homology
with the cortical thymocyte markers for the Xenopus (CTX)
family, indicating that possible V-C2 domain ancestors ofMHC
or T-cell receptors (TCR) had evolved through gene duplication
of ancestral CTX family precursor genes (Chretien et al. 1998;
Du Pasquier et al. 1999). The three classical JAMs share 32–
38 % sequence identity (Aurrand-Lions et al. 2000) while they
share only 14-18 % with the other related non-classical family
members JAM-4, JAM-L, CAR or ESAM. The non-classical
JAMs differ from the classical JAMs mainly by their cytoplas-
mic tail. Indeed JAM-A, -B and –C have relatively conserved
cytoplasmic sequences containing a type II PDZ binding motif
at the cytoplasmic C-terminus (Bradfield et al. 2007a). This
PDZ binding motif can interact with various intracellular scaf-
fold proteins and forms polarity complexes (Ebnet et al. 2003;
Mandell and Parkos 2005). The non-classical JAMs have a
longer cytoplasmic tail at the C-terminal part containing a type
I PDZ binding motif. The molecules JAM-A and –C can be
processed by metalloproteinase such as ADAM-10 or ADAM-
17, leading to shedding from endothelial cell surfaces and
release as a soluble factor (Koenen et al. 2009; Rabquer et al.
2010; Salifu et al. 2007). Soluble JAMs may function as
adhesion inhibitors or induce chemotactic signals for endothe-
lial cells (Rabquer et al. 2010). This process has not been shown
for JAM-B and still remains an area of investigation.
JAMs can also form homophilic and heterophilic interac-
tions in trans- and cis-configurations (Fig. 1 and Table1).
JAM-A is able to interact heterophilically with the leukocyte
integrin CD11a/CD18 (LFA-1) (Ostermann et al. 2002) and the
endothelial integrin αvβ3 (Naik et al. 2003) and is the receptor
of the reovirus attachment protein σ-1 (Barton et al. 2001).
JAM-B can form heterophilic interactions with JAM–C, which
are of higher affinity than homophilic interactions and with the
leukocyte integrin α4β1 (VLA-4, CD49d/CD29) (Arrate et al.
2001; Cunningham et al. 2002). JAM–C has even more possi-
ble partners and has been shown to bind to the leukocyte
integrins αMβ2, αXβ2, αVβ3 and CAR (Lamagna et al.
2005; Li et al. 2009; Mirza et al. 2006; Santoso et al. 2002).
The non-classical family members can also form multiple
interactions. The molecule JAM-L is able to bind to non-
activated α4β1 integrin and CAR (Luissint et al. 2008; Zen
et al. 2005). CAR is able to bind to JAM–C and JAM-L (Zen
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et al. 2005;Mirza et al. 2006). Concerning JAM-4 and ESAM,
no heterophilic interaction has so far been described.
The protein structure for JAM-A has been devised using X-
ray crystallography studies. In these studies, it was shown that a
three amino acid sequence (Val-Leu-Val) in the linker of the two
immunoglobulin-like domains allows the distal Ig-like domains
to bend and another three amino acid sequence (Arg-Leu-Glu)
in the V type Ig-like domain to bind and dimerize (Kostrewa
et al. 2001; Prota et al. 2003). A dimer of JAM-A at the surface
of a cell will be able to interact in trans with another JAM-A
dimer expressed by the adjacent cell and thus form a tetramer.
At the apical cell border, the successive JAMs tetramer could
form a kind of zipper structure surrounding the cell (Kostrewa
et al. 2001). The same type of dimerization motif is found in
JAM-B (Arg-Leu-Glu) and JAM–C (Arg-Ile-Glu) suggesting
that they can form dimers in the same way as JAM-A.
The cytoplasmic portion of the JAMs can mediate protein-
protein interaction through their PDZ binding motif. The
motif Phe-Leu-Val of JAM-A interacts with proteins contain-
ing type II PDZ such as ZO-1, AF-6, CASK, PAR-3 and
MUPP-1 (Ebnet et al. 2000; Hamazaki et al. 2002; Itoh et al.
2001; Martinez-Estrada et al. 2001). The other JAMs also
contain a PDZ binding motif of type II (JAM-B and –C) or
a type I (CAR, ESAM, JAM-4). So far, the bindings of the
following PDZ proteins have been identified: JAM-B and –C
bind PAR-3 (Ebnet et al. 2003), CAR binds LNX2, ZO-1,
MUPP-1 and MAGI-1 (Cohen et al. 2001; Coyne et al. 2004;
Excoffon et al. 2004; Sollerbrant et al. 2003), JAM-4 binds
MAGI-1 and LNX1 (Hirabayashi et al. 2003; Kansaku et al.
2006) and ESAM bind to the MAGI-1 protein (Wegmann
et al. 2004). The molecule JAM-L is the only JAM family
member that does not contain a PDZ binding motif and as a
consequence is thought not to bind to any PDZ protein.
Through this extensive array of extracellular and intracel-
lular interactions, it is thought that JAMs can participate in a
diverse array of cell functions such as cell polarity, permeabil-
ity and leukocyte migration. We will discuss some of these
functions later in this review.
Identification and expression pattern of JAMs (Table 2)
The first member of the JAM family to be discovered was
JAM-A (Martin-Padura et al. 1998). It was identified in a
Fig. 1 JAM family and interactions. a. The JAM family is composed of 7
members with structural homology; two extracellular Ig-like domains, a
transmembrane portion and a cytoplasmic tail. In the cytoplasmic por-
tion, classical JAMs (A, B and C) contain a type II PDZ binding motif.
Members of the non-classical JAM family (CAR, ESAM and JAM-4)
contain a type I PDZ binding motif. Both motifs can bind multiple
intracellular partners (AF-6, MUPP-1, ZO-1, PAR-3, MAGI-1, LNX
and CASK). b. JAMs can form homophilic interactions via their intra-
cellular domains and can also form cis- or trans-interactions with other
JAM family members or integrins
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mouse endothelioma cell line as a surface antigen recognized
by the antibody BV11 and characterized by expression at the
TJs of endothelial and epithelial cells (Martin-Padura et al.
1998). In a separate study, this protein had already been
characterized as a platelet receptor molecule recognized by
the antibody F11 (F11R) (Sobocka et al. 2000). Soon after,
two other JAMs were identified in endothelial cells, JAM-B
(VE-JAM, human JAM2) and JAM–C (human JAM3 or
mouse JAM2) (Arrate et al. 2001; Aurrand-Lions et al.
2001a; Cunningham et al. 2000; Palmeri et al. 2000). In order
to standardize the nomenclature, the laboratories working on
JAMs agreed with the designated terms JAM-A, -B and -C in
2002 and this was published by William A. Muller in 2003
(Muller 2003).
When transfected into polarized epithelial and endothelial
cells, classical JAMs are found in the region of TJs. However,
we found that they localized to distinct sub-compartments
of the junction. Specifically, JAM–C was found to co-
localize with ZO-1 at the TJs in MDCK cells, whereas
JAM-A co-localized only partially with ZO-1 and JAM-B
appeared to be more diffuse at the lateral membrane
(Aurrand-Lions et al. 2001b). Furthermore, the heterogeneous
expression pattern of the JAM family members in different
organs reflects the heterogeneity of intercellular junctions and
potential tissue-specific functions. JAM-A, for example, is
highly enriched on the blood–brain barrier (BBB), where the
TJs are known to have a lower permeability (Aurrand-Lions
et al. 2001b). Conversely, high endothelial venules (HEV) and
lymphatic endothelial cells, which can support constitutive
trafficking of leukocytes, have high expression levels of
JAM-B and -C but low levels of JAM-A (Aurrand-Lions
et al. 2001b) (Table 2).
The non-classical JAM family member ESAM was identi-
fied in a hybridization screen of genes expressed by human
umbilical vein endothelial (HUVEC) cells under migratory
conditions (Hirata et al. 2001). In this study, the authors
characterized the homology of the structure of ESAM and
other JAM family members. Northern blot and in situ hybrid-
ization revealed that ESAM expression is restricted to endo-
thelium, whereas JAM-A is expressed on endothelial and
epithelial cells. In murine tissue, ESAM is preferentially
expressed in highly vascularized tissues such as the heart
and lung (Hirata et al. 2001). In mouse embryos, ESAM
expression is observed in blood vessels at an early stage of
development (E8.5–9.5). Another study confirmed the endo-
thelial specificity of ESAM expression and colocalization at
the TJ with ZO-1, occludin and claudins (Nasdala et al. 2002).
In 2009, Stalker et al. (2009) identified ESAM expression on
the surface of platelets confirming a broader expression profile
for this molecule (Table 2).
The non-classical JAM family member CAR was original-
ly characterized as a receptor for the coxsackie virus and
adenoviruses (Bergelson et al. 1997; Mapoles et al. 1985). It
was only in later studies that it was identified as a TJ component
colocalizing with ZO-1 in epithelial cells (Cohen et al. 2001).
The expression profile for this molecule is not restricted to
polarized cells, as it is also expressed by myocardial cells
(Noutsias et al. 2001). Human, mouse and rat CAR mRNA
were detected mainly in the heart, brain, pancreas, kidney and
liver (Fechner et al. 1999) and in rat the protein was also
detected in epithelial cells in liver, intestines, brain, lung
and kidney (Tomko et al. 2000).
The non-classical JAM family member, JAM-4, was iden-
tified in a screen searching for integral membrane proteins that
interacted with MAGI-1 in a yeast two-hybrid assay using
PDZ domains of human MAGI-1 as a probe (Hirabayashi
et al. 2003). JAM-4 is expressed in liver, kidney, stomach,
intestine and skeletal muscle with lower levels observed in
lung. Furthermore, immunofluorescence studies have con-
firmed that JAM-4 is localized at TJ in various epithelial cell
populations and colocalized with ZO-1 and MAGI-1
(Hirabayashi et al. 2003).
Table 2 Expression of JAMs
Cell expression Tissue expression
JAM-A Endothelial, epithelial cells, leukocytes and platelets
(Martin-Padura et al. 1998; Sobocka et al. 2000)
Brain, liver, kidney, pancreas, heart, lymph node, intestine,
lung, placenta, skin, cornea (Martin-Padura et al. 1998)
JAM-B Vascular and lymphatic endothelial cells (Aurrand-Lions
et al. 2001a; Cunningham et al. 2000; Palmeri et al. 2000)
Brain, lymph node (HEV), skin, placenta, testis, heart, lung
(Aurrand-Lions et al. 2001a; Palmeri et al. 2000)
JAM-C Vascular and lymphatic endothelial cells, platelets
and leukocytes (human) (Arrate et al. 2001)
Brain, lymph node (HEV), skin, cornea, placenta, testis, heart,
lung, smooth muscle, uterus (Arrate et al. 2001)
CAR Endothelial, epithelial cells, cardiomyocytes
(Cohen et al. 2001) (Noutsias et al. 2001)
Cornea, skin, brain, prostate, testis, pancreas (Fechner et al.
1999; Mirza et al. 2006; Tomko et al. 2000)
ESAM Endothelial cells (Hirata et al. 2001; Wegmann et al. 2004)
platelets (Stalker et al. 2009)
Lung, heart, skin, kidney, embryos (Hirata et al. 2001)
JAM-L Leukocytes (Guo et al. 2009; Luissint et al. 2008;
Moog-Lutz et al. 2003)
Hematopoietic tissue (Guo et al. 2009; Luissint et al. 2008)
JAM-4 Epithelial cells, germ cells (Hirabayashi et al. 2003)
(Nagamatsu et al. 2006)
Liver, stomach, intestine, skeletal muscle, lung
(Hirabayashi et al. 2003)
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As mentioned, the structure of JAM-L is different from the
other JAM family members, as it does not contain a PDZ
binding motif and is not expressed by endothelial or epithelial
cells. It was identified by screening for retinoic acid-induced
gene expression in leukemia promyelocytes (Moog-Lutz et al.
2003). JAM-L expression is found in mature hematopoietic
cells and localized at cell–cell contacts with vascular endothe-
lium (Moog-Lutz et al. 2003). Another study confirmed that
JAM-L expression is restricted to the leukocyte sub-
populations neutrophils, monocytes and memory T-cells
(Luissint et al. 2008) (Table 2).
JAMs in endothelial barrier permeability
Cell polarity
JAMs are associated with several cytoplasmic polarity pro-
teins indicating a role in the formation of cell junctions and
cell polarity (Table 1). As discussed, most of these cytoplasmic
partners contain a PDZ binding motif that can interact with the
C-terminal part of JAMs. For example classical JAMs all interact
with ZO-1, which also associates with the two other types of
junctional molecules, occludin and the claudins (Mitic and
Anderson 1998; Tsukita et al. 2001). This is of particular
functional relevance as ZO-1 can also interact with actin
(Fanning et al. 1998). It is thought that ZO-1 may recruit
JAMs and retain them in junctions by protein stabilization.
Another important cytoplasmic partner of JAMs is AF-6
(Afadin) (Ebnet et al. 2000). Interaction between JAMs and
AF-6 may be important during the early stages of junction
formation, as the two molecules colocalize in early nascent
spot-like junctions (Asakura et al. 1999; Ebnet et al. 2001).
Further studies have shown that AF-6 recruits JAM-A to
junctions, as microinjection of JAM-A into epithelial cells
resulted in localization of JAM-A only at sites where AF-6
is present (Ebnet et al. 2000). The same type of experiments
revealed that the presence of ZO-1 at cell–cell contacts was
not sufficient to recruit JAM-A (Ebnet et al. 2000; Fukuhara
et al. 2002).
JAM-A is also able to interact with PAR-3 in a PDZ-
dependent manner. This was demonstrated by an ectopic
expression model, where induced expression of JAM-A led
to recruitment of PAR-3 to cell–cell contacts (Ebnet et al.
2001; Itoh et al. 2001). The molecule PAR-3 can form molec-
ular complexes with atypical protein kinase C (aPKC) and
PAR-6, which are thought to participate in cell polarization
(Suzuki and Ohno 2006). Indeed, the overexpression of mu-
tated polarity complex proteins in cells during the course of
cell polarization led to the delocalization of TJ molecules and
a disruption in endothelial function (Gao et al. 2002; Nagai-
Tamai et al. 2002; Suzuki et al. 2001; Yamanaka et al. 2001).
Therefore, JAM-A may play a critical role in maintaining cell
polarization through anchoring the PAR-3-PAR6-aPKC com-
plex at the cellular junction.
Polarization of immature junctions starts with the forma-
tion of adherens junctions (Mitic and Anderson 1998). In
epithelial cells, it starts with nascent spots of contact between
lamellipodia of adjacent cells containing E-cadherin, ZO-1
and JAM-A (Ebnet et al. 2001; Suzuki et al. 2002). JAM-A
then, through the activation of cdc42 and/or Rac1, recruits the
polarity complex to the junction (PAR-3-PAR6-aPKC)
(Yamanaka et al. 2001) (Fig. 2).
As discussed, blocking JAM-A antibodies can increase
transendothelial or transepithelial permeability through dis-
ruption of JAM-A distribution at the TJ. However, some
junctional integrity is maintained as it does not interfere with
E-cadherin and ZO-1 recruitment to the contact sites (Liang
et al. 2000; Liu et al. 2000). A disruption in junction formation
is also observed when blocking the PAR-3-PAR6-aPKC com-
plex where only immature adherens junctions can be formed.
Similar to JAM-A, JAM-B and -C can also associate with
PAR-3 and ZO-1 in a PDZ-domain-dependent manner (Ebnet
et al. 2003). Neither JAM-B nor -C has been identified in
epithelial cells suggesting that the potential existence of a
JAMB/C-PAR3 complex may be restricted to endothelial cells
(Ebnet et al. 2003). However, JAM-C was shown to be
essential for spermatid polarity as it participates in the recruit-
ment of polarity proteins such as PAR6, cdc42, PKCλ and
PATJ (Gliki et al. 2004). Interestingly, PAR-3 is highly spe-
cific for the classical JAMs, as ESAM and CAR do not
interact with this polarity complex factor, nor do they with
other components of TJs such as occludin and the claudins
(Ebnet et al. 2003; Ebnet et al. 2001). Clustering of JAM-A at
TJs was also responsible for recruitment of molecules in-
volved in cell polarity formation such as PAR-3, ZO-1, ZO-
2, PDZ-GEF1 and GTPase Rap2c (Monteiro et al. 2013).
Barrier properties and inflammation
JAM-A also regulates tight epithelial morphology through the
modulation of integrin β1 by the small GTPase molecule
Rap1 (Mandell et al. 2005). In this in vitro study, JAM-A
knockdown by siRNA increased epithelial cell permeability.
A similar observation was made with the expression of a
mutant JAM-A lacking the homodimerization domain, sug-
gesting that JAM-A functions on epithelial cell morphology
and TJs only as a homodimer (Mandell et al. 2005). Recently,
using epithelial or fibroblast cells transfected with JAM-A or -
C mutant, it was shown that serine phosphorylation brings
JAM-A and -C into TJs and as a result reduces permeability
of the cell layer (Iden et al. 2012; Mandicourt et al. 2007). At
least for JAM-A, it can be concluded that phosphorylation was
due to the activity and colocalization of aPKC at Serine 285,
as a knockdown of this enzyme by siRNA reversed the effect
of JAM-A localization in TJs and increased cell permeability.
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In line with this finding, increased permeability of the gut
epithelial layers was observed in a colitis model with JAM-A-
deficient mice (Khounlotham et al. 2012). Furthermore, in
corneal endothelium, JAM-A, -C and CAR are expressed
but only JAM-A is localized at the TJ and colocalized with
ZO-1 and AF-6. In a calcium depletion and recovery assay, an
anti-JAM-A antibody was able to induce corneal swelling due
to impaired barrier function. Thus, this study has shown an
essential role for JAM-A in the functionality of the corneal
endothelial barrier (Mandell et al. 2006).
Tissue or systemic inflammation induces an increased per-
meability of blood vessels and epithelium allowing leukocytes
to migrate to the site of inflammation (Johnson-Leger and
Imhof 2003). As JAMs are important regulators of epithelial
and endothelial cell polarity, it is clear they can play a pivotal
role in the inflammatory process. As discussed previously, an
inflammatory stimulus can alter the subcellular localization of
JAMs and affect tissue permeability. For example, in vitro
stimulation of endothelial cells by TNF-α/IFN-γ or FGF2 has
been shown to induce JAM-A redistribution to the luminal
side (Fig. 3) (Naik et al. 2003; Ostermann et al. 2002; Ozaki
et al. 1999). JAM-C is also partially redistributed to the
luminal side of endothelial cells upon oxLDL stimulation
(Keiper et al. 2005) (Fig. 3). As already mentioned, JAM-A-
deficient mice exhibit a defect in permeability on the intestinal
lining. Under steady state conditions, the barrier shows an
almost normal morphology but under inflammatory condi-
tions, infiltration of PMN and protective lymphocytes can
massively increase due to a reduced barrier function
(Khounlotham et al. 2012; Laukoetter et al. 2007). Although
these immune cells exert a protective function against infec-
tion, the clinical score of JAM-A-deficient mice is worse
while the mucosa presents less injury and more proliferation
(Khounlotham et al. 2012; Laukoetter et al. 2007).
In quiescent microvascular endothelial cells, JAM-C is
mostly localized in the cytoplasm and is recruited to the
junction upon VEGF stimulation. Under these conditions,
JAM-C can regulate paracellular permeability through modu-
lation of actomyosin-dependant contractility and VE-
cadherin-mediated cell–cell contact (Lamagna et al. 2005;
Orlova et al. 2006). Vascular permeability is increased in
thrombin-stimulated endothelial cells that overexpress JAM-
C and this might be due to coupling of JAM-C and β3
integrins (Li et al. 2009).
Blood–brain barrier (BBB)
The BBB plays an essential role in maintaining the homeo-
stasis of the central nervous system (CNS). The barrier
properties are maintained by the TJs and are characterized
by very low rates of vesicle transport and a marked reduction
in permeability (Engelhardt and Ransohoff 2012).
Interestingly, brain capillaries in the early embryo are perme-
able to small molecules that cannot normally enter the adult
brain. However, the BBB starts to develop an enhanced barrier
function at around E13–E15 that is not completed until after
birth (Wolburg and Lippoldt 2002). Several studies have
shown a role for astrocytes in the establishment of the BBB
that requires direct contact with the blood vessels (Tao-Cheng
et al. 1987) or by secretion of soluble factors in close proxim-
ity to the vessel (Arthur et al. 1987; Wolburg et al. 1994).
Whilst this micro-environmental niche maintained by astro-
cytes seems to be necessary to induce and maintain the BBB,
other factors are also required to sustain the functionality of
this structure (Rubin et al. 1991; Wolburg et al. 1994).
A breakdown in the BBB function can lead to serious
damage within the CNS and a perturbation in brain function.
Several diseases can lead to BBB damage through partial
Fig. 2 Role of JAMs in cell polarization. JAM-A is known to be present
in the early contact points between epithelial cells, along with E-cadherin.
It is stabilized at the junction being formed by interacting with ZO-1 and
AF-6, which links JAM-A to the actin cytoskeleton. To form a mature
junction, the polarity complex PAR-3/PAR-6/aPKC has to be recruited.
JAM-A participates through the activation of cdc42 and Rac1. JAM-A
also contributes to PDZ-GEF1 and Rap2c recruitment to the junction. In
the later stage of junction formation and stabilization, the TJ molecules
occludin and the claudins are recruited to stabilize and form mature cell-
cell junctions
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impairment or total breakdown, such as the development of
tumors, stroke, multiple sclerosis, hypertension and encepha-
litis (Wong et al. 2013).
We mentioned the BBB here, since JAM-A, -B and -C are
often localized and function at the intercellular junctions of
BBB capillaries (Aurrand-Lions et al. 2001b; Martin-Padura
et al. 1998; Padden et al. 2007; Vorbrodt and Dobrogowska
2004). Interestingly, a homozygotic JAM-C mutation was
recently found in a consanguineous family in the United
Arab Emirates that has provided an insight into the role of
this molecule in humans. Some members of this family de-
velop an autosomal-recessive syndrome leading to brain hem-
orrhage, subependymal calcification and cataracts (Mochida
et al. 2010). In this study, they mapped the disease locus
on the chromosome 11q25. Further sequence analysis of
genes revealed a mutation in the intron 5 of JAM3. RT-PCR
analysis of patient cells confirmed abnormal splicing, which
results in an early termination of translation. This suggests an
important role for JAM-C in maintaining the integrity of the
BBB (Mochida et al. 2010). Moreover, a study using JAM-C-
deficient mice revealed that mice backcrossed onto a C57BL6
background develop hydrocephalus characterized by enlarged
ventricles and disrupted brain fluid circulation (Wyss et al.
2012).
Recently, JAM-A has been implicated in regulating leuko-
cyte trafficking across the BBB in HIV infection models
(Williams et al. 2013). This study demonstrated that upon
HIV infection, CD14+CD16+ monocyte transmigration
across the BBB is facilitated by increased expression of
JAM-A, ALCAM, CD99 and CD31. In addition, this study
confirmed that antibodies against JAM-A reduced the number
of transmigrating monocytes irrespective of HIV infection
status, indicating a broader role for this molecule in leukocyte
trafficking (Williams et al. 2013). Furthermore, in a model of
rat cortical cold-injury, JAM-A expression was lost at the
lesion site 12 h after injury, while 2 days later the level of
expression was back to normal. This loss of expression was
concomitant to the BBB breakdown and demonstrates an
Fig. 3 JAMs regulation upon inflammatory condition. In resting endo-
thelium, JAMs are localized at the lateral membrane in the junctional
zone. Upon inflammatory stimuli with TNF-α, IFN-γ, or OxLDL, JAMs
are relocalized onto the luminal surface of the endothelial membrane
where they can interact with circulating leukocytes or be processed into
soluble forms by metalloproteinases. This relocalization of JAM-A in-
creases endothelium permeability and is characterized by a decrease in
electrical resistance
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essential role for JAM-A in supporting BBB integrity (Yeung
et al. 2008).
JAMs in leukocytes transmigration
Leukocyte trafficking across an epithelial or endothelial bar-
rier is an essential process in inflammation and the immuno-
surveillance. This process involves several distinct steps that
include rolling on the luminal endothelial layer, which is
followed by firm adhesion and diapedesis (Garrido-Urbani
et al. 2008). The last step can use a paracellular route along
adjoining endothelial cell–cell contacts or by transcytosis,
where the leukocytes pass through the body of endothelial
cells by forming a channel (Fig. 4). The process of transcytosis
appears to be a minor route of access and has been mostly
observed in vitro with neutrophils and in brain vessels in vivo
(Muller 2011). An inflammatory stimulus can lead to the rapid
redistribution of JAMs on endothelial and epithelial cells,
which has important implications in leukocyte transmigration.
In the following part of this review, we will discuss the role of
each JAM in the process of transmigration, with a particular
focus on the endothelium (Fig. 4).
JAM-A
The laboratory of Elisabetha Dejana, which discovered JAM-
A through its interaction with the antibody BV11, has studied
the role of this molecule in leukocytes transmigration. In an
air-pouch model, they observed that the BV11 antibody
inhibited recruitment of leukocytes to the site of inflammation
(Martin-Padura et al. 1998). In vitro, they have also shown
that the antibody inhibited monocyte transmigration in a static
migration assay (Martin-Padura et al. 1998). This antibody
specifically recognized JAM-A dimers but not monomers,
indicating that a dimeric form of JAM-A is required for
transmigration (Bazzoni et al. 2000). Moreover, intravenous
injection of the BV11 antibody reduced leukocytes infiltration
into the cerebrospinal fluid and cytokine-induced BBB per-
meability (Del Maschio et al. 1999). A later study has gone
Fig. 4 Implication of JAMs in leukocyte transmigration. Migration of
leukocytes across endothelium can be separated into distinct steps,
rolling, adhesion, diapedesis and reverse transmigration. Under inflam-
matory conditions, JAMs are localized onto luminal surfaces of the
endothelium and are able to interact with integrins on leukocyte surfaces.
Along with PECAM-1 and CD99, JAM-A contributes to the migration of
leukocytes in-between endothelial cells by diapedesis. In some cases
where leukocytes cannot pass through the basal membrane, the leukocyte
can exit the ablumenal compartment by reverse transmigration. This
process is regulated by JAM-C. Leukocytes are able also to pass across
the endothelium using a transcellular route. This process is regulated by
CD99, PECAM-1, ICAM-1 and JAM-A
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further and shown that JAM-A controls leukocytes
transendothelial migration through a direct interaction be-
tween LFA-1 (CD11a/CD18) and the C2 domain of JAM-A
(Ostermann et al. 2002). In this study, it was observed that
endothelial cells stimulated with PMA or the chemokine
CXCL12 led to a reduction of T-lymphocyte and monocyte
arrest on the endothelial layer in the presence of JAM-A
blocking antibodies (Ostermann et al. 2002). The heterophilic
interaction between JAM-A and LFA-1 has a higher affinity
than homophilic JAM-A/JAM-A interaction (Ostermann et al.
2002). It has been proposed that, under resting conditions,
JAM-A engages in homophilic interactions at cell–cell con-
tacts but upon inflammation JAM-A relocalizes to the apical
cell membrane where it can then interact with LFA-1 of
neutrophils (Ostermann et al. 2002). This mechanism may
promote the recruitment of leukocytes across the vascular
barrier by enhancing cell adhesion events at the endothelial
surface (Ozaki et al. 1999). However, not all studies are
consistent with this finding, as several other anti-JAM-A
antibodies are unable to block leukocyte transmigration
(Lechner et al. 2000; Liu et al. 2000). Furthermore, the stim-
ulation of endothelium with inflammatory cytokines has been
shown to have no effect on JAM-A-dependent leukocyte
transmigration under flow conditions (Shaw et al. 2001).
Other results obtained with JAM-A-deficient mice support
these in vitro data where neutrophils trans-endothelial migra-
tion was reduced (Cera et al. 2004). In a model of acute lung
injury, migration of neutrophils to the alveolar space is re-
duced in JAM-A-deficient animals or in the presence of anti-
JAM-A antibodies (Cera et al. 2004). However, in another
study, it was shown that blocking of JAM-A does not neces-
sarily correlate with reduced lung injury (Lakshmi et al.
2012). Surprisingly, the migration of dendritic cells (DC) to
lymph nodes was shown to increase in JAM-A-deficient mice.
This was shown to be due to a promigratory phenotype of DCs
lacking JAM-A and was associated with enhanced contact
hypersensitivity (Cera et al. 2004). Consistent with these
findings, another study also described an increased migration
of JAM-A-deficient DCs and T-cells to tumor sites (Murakami
et al. 2010).
Intravital microscopy using mouse venules in cremaster
muscle of different gene-deficient animal strains, has demon-
strated a sequential action of ICAM-2, JAM-A and PECAM-1
during transendothelial migration of neutrophils after IL-1
stimulation (Woodfin et al. 2009). Intriguingly, when inflam-
mation was stimulated by TNF-α, these molecules are not
required for leukocyte transmigration (Woodfin et al. 2009).
Further experiments confirmed a differential effect and usage
of molecular mechanisms by transendothelial migrating neu-
trophils. Specifically, a reduction in migration was observed in
JAM-A-deficient mice (or in the presence of an anti-JAM-A
(BV11) antibody) when a tissue compartment was stimulated
with IL-1, or in ischemia and reperfusion models but this was
not the case after stimulation by leukotriene or PAF (Woodfin
et al. 2007). This is consistent with the redistribution of JAM-
A being dependent on the type of stimuli and is supported by
observations where JAM-A is redistributed with TNF-α stim-
ulation but not with phorbol ester (Shaw et al. 2004). A more
recent study has shown a role for endothelial JAM-A in
monocyte recruitment into atherosclerotic plaques, using
endothelium-specific JAM-A-deficient mice bred with
ApoE-deficient mice (Schmitt et al. 2013). The endothelium-
specific JAM-A deficiency led to reduced monocyte migra-
tion through the arterial wall, which contrasted with
leukocyte-specific JAM-A deficiency, which exhibited in-
creased vascular permeability and lesion formation.
Apart from the role of JAM-A in paracellular transmigration
of leukocytes, it has also been implicated in regulating the
transcellular migratory route through an endothelial cell. In an
in vitro study with HUVEC cells, it has been shown that JAM-
A is part of a molecular complex that surrounds the leukocyte
(neutrophils or monocytes) migrating through the membrane
channel formed by the endothelial cells, together with CD31
and CD99 (Mamdouh et al. 2009). This role appears not to be
essential, as JAM-A blockade does not affect this process,
which is in contrast to CD31 and CD99 (Mamdouh et al. 2009).
JAM-B
As discussed, vascular JAM-B interacts with JAM-C and the
integrin α4β1. This integrin has previously been described as
mediating memory T-lymphocyte adhesion to inflamed
endothelium through VCAM-1 (Butcher and Picker 1996).
At present, it is not clear whether the integrin can simulta-
neously engage VCAM-1 and JAM-B through different bind-
ing sites. However, it is also possible that JAM-B and VCAM-
1 may interact laterally and obtain integrin reinforcement by
conformational changes. This may explain why JAM-B/α4β1
interactions require JAM-B to engage with JAM-C in cis prior
to this interaction (Cunningham et al. 2002). Other recent
studies have proposed an independent role of JAM-B in
leukocyte transmigration. Ludwig et al. (2005) demonstrated
that anti-JAM-B and anti-JAM-C antibodies had an additive
effect on blocking leukocytes infiltration in a model of allergic
contact dermatitis. In a later study using a model of DNFB-
induced contact hypersensitivity, JAM-B was shown to have a
role in rolling and firm adhesion of T-lymphocytes through an
interaction with α4β1 (Ludwig et al. 2009).
JAM-C
As mentioned previously, JAM-C is expressed on endothelial
cells and human lymphocytes and can play a role in regulating
leukocyte transmigration. The first study supporting this hy-
pothesis came by enforced expression of JAM-C on endothe-
lioma cell lines. These cells could support increased rates of
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leukocyte transmigration and this could be abrogated using
anti-JAM-C antibodies (Johnson-Leger et al. 2002). This ef-
fect may be due to a homophilic interaction between
multimers of JAM-C and JAM-B in trans or in cis formations
(Santoso et al. 2002; (Arrate et al. 2001; Liang et al. 2002).
Several other groups have implicated JAM-C in regulating
leukocyte migration in different disease contexts. In rheuma-
toid arthritis patients and animal models, JAM-C overexpres-
sion has been observed in endothelial cells and has been
proposed to play a role in leukocyte adhesion and retention
within the inflamed synovium (Rabquer et al. 2008). In a
diabetes-type I model (RIP-LCMV), JAM-C has been impli-
cated in the recruitment of pathogenic T-lymphocytes into
Langerhans islets (Christen et al. 2013). These transgenic
mice express ing a pro te in o f the lymphocy t i c
choriomeningitis virus (LCMV) in β-cells, became diabetic
after infection with LCMV virus. The authors found that,
upon infection, JAM-C protein was upregulated near the
islets. Moreover, JAM-C blockade with a neutralizing anti-
JAM-C antibody was able to reduce the incidence of type 1
diabetes. Similarly, in an ischemia and reperfusion model,
JAM-C has been shown to regulate leukocyte transmigration
(Scheiermann et al. 2009). In this study, they described that
soluble JAM-C injected into mice as a pretreatment is able to
inhibit leukocyte migration into zones of ischemia of the
kidney and the cremaster muscle. Furthermore, leukocyte
adhesion and transmigration, analyzed by intravital microsco-
py of the cremaster muscle model, was suppressed in JAM-C-
deficient mice and enhanced in mice overexpressing JAM-C
specifically in the endothelium (Scheiermann et al. 2009).
However, a role for JAM-C beyond that of simple transmi-
gration has been supported by a number of recent publica-
tions. A study in 2007 using blocking antibodies and JAM-C
overexpression showed no effect of JAM-C on neutrophil
transmigration across HUVECs (Sircar et al. 2007). This
implies that the effect of JAM-C blockade on leukocyte traf-
ficking in vivo may extend beyond that of the initial recruit-
ment phase. This is supported by an extended in vitro study in
which JAM-C has been shown to play a role in the reverse
transmigration of monocytes, confirming that post-
transmigratory events can be regulated by molecules such as
JAM-C (Bradfield et al. 2007b). This process was first ob-
served in vitro and has now been confirmed in vivo by 3D
intravital microscopy (Woodfin et al. 2011). Both studies
demonstrated that a proportion of transmigrated neutrophils
or monocytes will reverse transmigrate back onto the luminal
surfaces and return to the vascular compartment. In the study
using monocytes, JAM-C-specific antibodies or JAM-C defi-
ciency increased the number of leukocytes that reverse
transmigrated (Bradfield et al. 2007b). This function may
serve to block an overactive inflammatory response.
However, this regulatory feedback loop may lead to reverse
transmigrated cells, identified by high ICAM-1 expression,
accumulating in the lungs where the secretion of reactive
oxygen species can lead to the induction of lung edema
(Woodfin et al. 2011). In conclusion, JAM-C promotes the
unidirectional transmigration of leukocytes as disrupting this
process by antibodies, or a reduction in gene expression, leads
to increased reverse transmigration and a return to blood flow.
Related JAMs
In an intravital microscopy study performed on ESAM-
deficient mice, neutrophil diapedesis was inhibited by 50 %
but the first steps of rolling and firm adhesion remained
unaffected (Wegmann et al. 2006). It has been shown that
ESAM is responsible for the maintenance of the tightness of
endothelial junctions and VEGF-induced vascular permeabil-
ity is affected by the absence of ESAM in knock-out animals
(Wegmann et al. 2006). A recent study has shown that ESAM
is also important for regulating monocyte migration during
atherosclerosis (Inoue et al. 2010). As monocytes do not
express ESAM, this result suggests that ESAM has another
ligand that has yet to be elucidated.
The interaction of JAM-L/CAR is involved in regulating
neutrophil, monocyte and T-cell transendothelial migration
across the inflamed endothelium (Guo et al. 2009; Luissint
et al. 2008; Zen et al. 2005). It has been shown that JAM-L is
expressed by granulocytes and monocytes and is a ligand of
CAR, which is present on the surface of endothelial cells (Guo
et al. 2009; Luissint et al. 2008; Zen et al. 2005). However,
JAM-L/CAR interactions can only be observed when leuko-
cytes either do not express the integrin α4β1 or when this
integrin is activated, otherwise JAM-L will form a complex
with the non-activated integrin α4β1 at the surface of
leukocytes.
Concluding remarks
The study of the JAM family has revealed these molecules as
having functional duality: controlling the immune cell re-
sponse through recruitment of leukocytes to sites of inflam-
mation and regulating the formation of cellular junctions in
epithelial and endothelial cells. Indeed, the JAMs participate
in the transmigration of leukocytes from blood to inflamed
tissue, by favoring the opening of the endothelial barrier for
crossing leukocytes. JAM-C controls even one-way leukocyte
traffic across the vascular barrier. At the same time, however,
JAMs are important for the formation and the maintenance of
endothelial junctions. Thus, there is clearly a dual role for
these molecules. Nevertheless, many questions remain unan-
swered. For example, in the classical JAM family (JAM-A, -B
and -C), several extracellular ligands for each JAM have
been identified, which is not the case for the non-classical
JAM family members. The molecule CAR has only two
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ligands and ESAM and JAM-4 have only been confirmed in
forming homophilic interactions.
Whilst the crystal structure of JAM-A has been fully elu-
cidated, which revealed a bending site in the linker domain
and a dimerization site in the V domain, this has not been
confirmed for the other JAMs. The molecules JAM-B and -C
present homology in these domains and a common mecha-
nism of multimerization has been proposed. However, no
study has as yet been conducted to confirm this binding
process, even though JAM-B/-C heterodimerisation is known
to take place.
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